Primary immunodeficiencies (PIDs) are a group of more than 400 potentially serious disorders, that can lead to frequent or severe infections, swellings and autoimmune problems. PID symptoms often appear in childhood, but some can first occur in adults.
The ASCIA Immunodeficiency Strategy for Australia and New Zealand is being developed by ASCIA, the peak professional body of clinical immunology and allergy specialists in Australia and New Zealand, in consultation with patient organisations (AusPIPs, HAE Australasia, IDFA and IDFNZ), and other stakeholders. Whilst the main content of the Strategy was completed in November 2020, the final version of the Strategy will be available in February 2022.
15 April 2020
ASCIA has developed a webpage in response to the COVID-19 infectious respiratory disease outbreak caused by the most recently discovered coronavirus at www.allergy.org.au/members/covid-19.
The webpage includes links to information about COVID-19 and primary immunodeficiency.
ASCIA is working in collaboration with patient organisations and other stakeholders to develop a ASCIA Immunodeficiency Strategy at a national level for both Australia and New Zealand.
The ASCIA Immunodeficiency Strategy’s Mission is to improve the health and wellbeing of people with PIDs (primary immunodeficiencies) and minimise the burden on individuals, carers, health services and community.
The ASCIA Immunodeficiency Strategy for Australia and New Zealand has the mission to improve the health and wellbeing of people with primary immunodeficiencies (PID), also known as inborn errors of immunity (IEI), and minimise the burden on individuals, carers, health services and community.